おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Kymab
company
About
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics.
- 101 - 250
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $100M
- Industries
- Biopharma,Biotechnology,Therapeutics
- Founded date
- Jan 1, 2010
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$150M
Kymab has raised a total of
$150M
in funding over 2 rounds. Their latest funding was raised on
Nov 24, 2016 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 24, 2016 | Series C | $100M | 1 | — | — | Detail |
| May 6, 2015 | Series B | $50M | 1 |
Malin Corporation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Kymab is funded by 1 investors.
Malin Corporation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Malin Corporation
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
